FHA
ORMP icon

First Horizon Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

First Horizon Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,750
Closed -$3.75K – 2451
2025
Q1 		$3.75K Buy
+1,750
New +$4.04K ﹤0.01% 1862

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

First Horizon Advisors's ORMP Position: Q2 2025 in Review

First Horizon Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q2 2025, closing a stake of 1,750 shares — an estimated $3.75K sold.

First Horizon Advisors first reported a position in ORMP in Q1 2025 and held it in 1 quarter. The position peaked at $3.75K in Q1 2025. 47 funds tracked by Wall St. Rank hold ORMP as of Q2 2025.

  • First Horizon Advisors reported no remaining Oramed Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • First Horizon Advisors sold 1,750 Oramed Pharmaceuticals shares in Q2 2025, an estimated $3.75K.
  • First Horizon Advisors first reported a position in Oramed Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • First Horizon Advisors's Oramed Pharmaceuticals position peaked at $3.75K in Q1 2025.
  • 47 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.